• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Early Serum Calprotectin (S100A8/A9) Predicts Delayed Cerebral Ischemia and Outcomes after Aneurysmal Subarachnoid Hemorrhage
【24h】

Early Serum Calprotectin (S100A8/A9) Predicts Delayed Cerebral Ischemia and Outcomes after Aneurysmal Subarachnoid Hemorrhage

机译：早期的血清CalProtectin（S100A8 / A9）预测动脉瘤蛛网膜瘤出血后的延迟脑缺血和结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To investigate the association of early serum calprotectin (S100A8/A9) level with disease severity and prognosis of patients with aneurysmal subarachnoid hemorrhage (aSAH). Patients and Methods: Serum samples were collected from 54 patients with aSAH (within 48 hours of onset) and 54 health controls. Levels of serum calprotectin were determined by enzyme linked immunosorbent assay. The clinical data of aSAH patients were collected. The prognosis was evaluated by modified Rankin scale at 3 months. Univariate and multivariable logistic regression analysis, bivariate correlation analysis and receiver operating characteristic (ROC) curve analysis were used respectively. Results: Serum calprotectin levels were significantly higher in aSAH patients than that in healthy controls (P < .001). The clinical severity was also significantly correlated with the level of serum calprotectin. Patients with poor prognosis at 3 months showed higher serum calprotectin levels within 48 hours of onset than that in patients with good prognosis (P = .002). The level of serum calprotectin within 48 hours was related to the complications of secondary pneumonia. Serum calprotectin can be used as an independent predictor for delayed cerebral ischemia (DCI) after aSAH and poor prognosis in patients with aSAH at 3 months. The ROC curve showed the cutoff value of calprotectin for predicting poor prognosis at 3 months was 6020 pg/ml (sensitivity: 53.57%, specificity: 96.15%), and the cutoff value for predicting DCI was 5275 pg/ml (sensitivity: 68.42%, specificity: 82.86%). Conclusion: Serum calprotectin concentrations within 48 hours after onset was significantly correlated with the clinical severity and the poor prognosis at 3 months in aSAH patients, suggesting that serum calprotectin may be a biomarker for early prediction of prognosis and complications in patients with aSAH and calprotectin may be a target for the treatment of aSAH.
机译：目的：探讨动脉瘤性蛛网膜下腔出血（aSAH）患者早期血清钙卫蛋白（S100A8/A9）水平与疾病严重程度及预后的关系。患者和方法：收集54例aSAH患者（发病48小时内）和54名健康对照者的血清样本。采用酶联免疫吸附法测定血清钙卫蛋白水平。收集aSAH患者的临床资料。3个月时采用改良Rankin评分法评估预后。分别采用单变量和多变量logistic回归分析、双变量相关分析和受试者操作特征（ROC）曲线分析。结果：aSAH患者血清钙卫蛋白水平显著高于健康对照组（P<0.001）。临床严重程度也与血清钙卫蛋白水平显著相关。3个月时预后不良的患者在发病48小时内的血清钙卫蛋白水平高于预后良好的患者（P=0.002）。48小时内血清钙卫蛋白水平与继发性肺炎的并发症有关。血清钙卫蛋白可作为aSAH后迟发性脑缺血（DCI）和aSAH患者3个月预后不良的独立预测因子。ROC曲线显示，钙卫蛋白预测3个月预后不良的临界值为6020 pg/ml（敏感性：53.57%，特异性：96.15%），预测DCI的临界值为5275 pg/ml（敏感性：68.42%，特异性：82.86%）。结论：aSAH患者发病后48小时内的血清钙卫蛋白浓度与临床严重程度和3个月后的不良预后显著相关，提示血清钙卫蛋白可能是早期预测aSAH患者预后和并发症的生物标志物，钙卫蛋白可能是治疗aSAH的靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号